Aerovate Therapeutics Files 8-K
Ticker: JBIO · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1798749
| Field | Detail |
|---|---|
| Company | Aerovate Therapeutics, INC. (JBIO) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Aerovate Therapeutics filed an 8-K on July 8th. Standard update, check exhibits for details.
AI Summary
On July 8, 2024, Aerovate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text. The company is incorporated in Delaware and headquartered in Waltham, Massachusetts.
Why It Matters
This 8-K filing indicates Aerovate Therapeutics is providing updates or submitting required documentation to the SEC, which could contain important operational or financial information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial disclosures that would indicate a high-risk situation.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- July 8, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Aerovate Therapeutics?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating it's a routine update or submission of required documentation.
When was this 8-K report filed?
The report was filed on July 8, 2024.
Where is Aerovate Therapeutics, Inc. headquartered?
The company's principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.
What is Aerovate Therapeutics' state of incorporation?
Aerovate Therapeutics, Inc. is incorporated in Delaware.
Does this filing reveal any specific financial performance or material events?
The provided text of the 8-K filing does not detail specific financial performance figures or material events; it primarily serves as a notification and filing of exhibits.
Filing Stats: 770 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-07-08 08:00:45
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share AVTE The Nasdaq
Filing Documents
- tmb-20240708x8k.htm (8-K) — 45KB
- tmb-20240708xex99d1.htm (EX-99.1) — 7KB
- tmb-20240708xex99d1001.jpg (GRAPHIC) — 6KB
- 0001798749-24-000042.txt ( ) — 186KB
- tmb-20240708.xsd (EX-101.SCH) — 3KB
- tmb-20240708_lab.xml (EX-101.LAB) — 16KB
- tmb-20240708_pre.xml (EX-101.PRE) — 11KB
- tmb-20240708x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On July 8, 2024, Aerovate Therapeutics, Inc. (the "Company") issued a press release announcing the decision to conduct a review of strategic alternatives focused on maximizing shareholder value. As part of this review process, the Company has engaged Wedbush Securities Inc. (Wedbush PacGrow) as the Company's exclusive strategic financial advisor. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "future," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," seek," "strategy," "should," "target," "will," "would" and similar expressions regarding future periods. These forward-looking statements include, but are not limited to, statements regarding the Company's review of strategic alternatives, the Company's ability to maximize shareholder value and the ability to complete a transaction as a result of the strategic review process. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including, without limitation, those risks and uncertainties set forth under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statem
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by Aerovate Therapeutics, Inc. on July 8, 2024 . 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aerovate Therapeutics, Inc. Date: July 8, 2024 By: /s/ George A. Eldridge George A. Eldridge Chief Financial Officer